Christian Hanson
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1083684302
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.
Across 225 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$714
- AstraZeneca$513
- Novo Nordisk$298
- Bayer$220
- Insulet Corporation$215
- Tandem Diabetes Care, Inc.$178
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,256100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 49 | $714 |
| AstraZeneca(2 entities) | 13 | $513 |
| Novo Nordisk | 18 | $298 |
| Bayer | 6 | $220 |
| Insulet Corporation | 7 | $215 |
| Tandem Diabetes Care, Inc. | 8 | $178 |
| Genentech USA, Inc. | 1 | $177 |
| Boehringer Ingelheim | 10 | $171 |
| Amgen | 8 | $143 |
| Antares Pharma, Inc. | 9 | $140 |
| Corcept Therapeutics | 7 | $128 |
| Amarin Pharma, Inc. | 8 | $124 |
| Abbott | 8 | $122 |
| Mannkind Corporation | 7 | $112 |
| Dexcom, Inc. | 7 | $102 |
| Novartis | 6 | $102 |
| Regeneron Healthcare Solutions, Inc. | 5 | $78 |
| Sanofi-aventis U.S. LLC | 5 | $75 |
| Esperion Therapeutics, Inc. | 4 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| AbbVie | 4 | $52 |
| Endo Pharmaceuticals Inc. | 3 | $45 |
| Sandoz | 3 | $42 |
| Radius Health, Inc. | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 3 | $37 |
| Nalpropion Pharmaceuticals LLC | 2 | $30 |
| Aytu Biopharma, Inc. | 2 | $26 |
| Gilead | 1 | $25 |
| Merck | 2 | $24 |
| Johnson & Johnson | 2 | $24 |
| Valeritas, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Medtronic | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Vistapharm, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,276 in reported general payments places this provider in the 60th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 18 | $19,136 |
| JardianceEmpagliflozin | 13 | $10,577 |
| SynthroidLevothyroxine Sodium | 15 | $1,056 |
| Ondansetron OdtOndansetron | 12 | $286 |
| Rosuvastatin Calcium | 14 | $164 |
| Atorvastatin Calcium | 12 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $298 | $19,13618 claims |
| Boehringer IngelheimJardiance | $171 | $10,57713 claims |
| AbbVieSynthroid | $52 | $1,05615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Tulsa
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Elie AbedTulsa$10K
- Vishnu Priya PulipatiTulsa$8K
- Maria VargasTulsa$7K
- Miguel Jara PalaciosTulsa$4K
- Deepa PhilipTulsa$4K
- Alekya PolojuTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.